@article{9428a3aa835b4fad85f23fee333f2cb8,
title = "Recent advances in “sickle and niche” research - Tribute to Dr. Paul S Frenette -",
abstract = "In this retrospective, we review the two research topics that formed the basis of the outstanding career of Dr. Paul S. Frenette. In the first part, we focus on sickle cell disease (SCD). The defining feature of SCD is polymerization of the deoxygenated mutant hemoglobin, which leads to a vicious cycle of hemolysis and vaso-occlusion. We survey important discoveries in SCD pathophysiology that have led to recent advances in treatment of SCD. The second part focuses on the hematopoietic stem cell (HSC) niche, the complex microenvironment within the bone marrow that controls HSC function and homeostasis. We detail the cells that constitute this niche, and the factors that these cells use to exert control over hematopoiesis. Here, we trace the scientific paths of Dr. Frenette, highlight key aspects of his research, and identify his most important scientific contributions in both fields.",
keywords = "hematopoietic stem cell, niche, sickle cell disease",
author = "Torres, {Lidiane S.} and Noboru Asada and Weiss, {Mitchell J.} and Andreas Trumpp and Toshio Suda and Scadden, {David T.} and Keisuke Ito",
note = "Funding Information: We are deeply saddened by the passing of Dr. Paul S. Frenette on July 26th, 2021. He was a visionary scientist, inspiring leader, devoted educator, and a kind friend. Paul's legacy will live on through his legacy at the Albert Einstein School of Medicine, including the myriad of trainees and faculty who he guided and mentored. The authors are grateful to members of the Einstein Stem Cell Institute for their comments on the topics of SCD and stem cell biology. N.A. and T.S. are supported by Grants-in-aid for Scientific Research (KAKENHI), T.S. is supported by the National Medical Research Council grant of Singapore Translational Research Investigator Award, and A.T. is supported by the Dietmar Hopp Foundation. M.J.W. D.T.S. and K. I. are supported by grants from the National Institutes of Health (P01HL053749 and R01HL156647 to M.J.W.; U19HL129903 to D.T.S.; and R01HL148852, R01DK098263, R01HL069438, and R01DK115577 to K.I.). L.S.T. is supported by the Paul S. Frenette Scholar Awards Program of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, and K.I. is a research scholar of the Leukemia & Lymphoma Society (#1360–19). Funding Information: We are deeply saddened by the passing of Dr. Paul S. Frenette on July 26 th , 2021. He was a visionary scientist, inspiring leader, devoted educator, and a kind friend. Paul{\textquoteright}s legacy will live on through his legacy at the Albert Einstein School of Medicine, including the myriad of trainees and faculty who he guided and mentored. The authors are grateful to members of the Einstein Stem Cell Institute for their comments on the topics of SCD and stem cell biology. N.A. and T.S. are supported by Grants-in-aid for Scientific Research ( KAKENHI ), T.S. is supported by the National Medical Research Council grant of Singapore Translational Research Investigator Award, and A.T. is supported by the Dietmar Hopp Foundation . M.J.W., D.T.S., and K. I. are supported by grants from the National Institutes of Health ( P01HL053749 and R01HL156647 to M.J.W.; U19HL129903 to D.T.S.; and R01HL148852 , R01DK098263 , R01HL069438 , and R01DK115577 to K.I.). L.S.T. is supported by the Paul S. Frenette Scholar Awards Program of the Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, and K.I. is a research scholar of the Leukemia & Lymphoma Society (# 1360–19 ). Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
month = jul,
day = "12",
doi = "10.1016/j.stemcr.2022.06.004",
language = "English (US)",
volume = "17",
pages = "1509--1535",
journal = "Stem Cell Reports",
issn = "2213-6711",
publisher = "Cell Press",
number = "7",
}